Interpreting Frontline ADC Trial Data in Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss key considerations when interpreting emerging frontline clinical trial data for antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer (mTNBC). The faculty emphasize that results from individual trials should be interpreted within the context of each study's design, including differences in patient populations, biomarker eligibility criteria, comparator chemotherapy regimens, and primary efficacy endpoints. NP Zafman explains why cross-trial comparisons should be approached with caution and highlights the importance of evaluating progression-free survival, duration of response, patient-reported outcomes, and quality-of-life measures when assessing the clinical relevance of emerging evidence. The discussion also explores the rationale for crossover in the ASCENT-03 study and how this design feature should be considered when interpreting overall survival outcomes. Throughout the segment, the speakers reinforce the importance of critically evaluating clinical trial methodology to appropriately apply emerging evidence to individualized treatment decisions for patients with metastatic triple-negative breast cancer.